

**PRESS RELEASE**

**28 February 2025 08:00:00 CET**

**Saniona's CEO, Thomas Feldthus, participates in Life Science-dagen on March 5 and in Redeye's Investor Forum Online on March 6, 2025**

**Saniona, a clinical-stage biopharmaceutical company, announces that the company's CEO, Thomas Feldthus, will participate at Life Science-dagen 2025 at Wallenberg's conference center, Gothenburg, on March 5 at 2:15 pm CET and at Redeye's Investor Forum Online on March 6 at 2 - 4 pm CET.**

Both events will be live broadcasted at [www.lifesciencedagen.se](http://www.lifesciencedagen.se) and at [Events - Redeye](#) respectively.

**For more information, please contact**

Thomas Feldthus, CEO, +45 22109957; [thomas.feldthus@saniona.com](mailto:thomas.feldthus@saniona.com)

**About Saniona**

Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of neurological disorders. Saniona's internal pipeline includes SAN2219, targeting acute repetitive seizures; SAN2355, addressing refractory focal onset seizures; and SAN2465, positioned for major depressive disorders. Saniona has two strategic development collaborations. SAN711 is being prepared for Phase 2 for essential tremor in collaboration with Acadia Pharmaceuticals and tesofensine is out licensed for obesity to Medix, which has submitted a market authorization application (MAA) in Mexico. In addition, Saniona oversees two clinical programs poised for collaboration. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease. Saniona partners include Acadia Pharmaceuticals, Boehringer Ingelheim GmbH, Productos Medix S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market. For more information, visit [www.saniona.com](http://www.saniona.com).

**Attachments**

**Saniona's CEO, Thomas Feldthus, participates in Life Science-dagen on March 5 and in Redeye's Investor Forum Online on March 6, 2025**